Clinical Report: Immune System Metabolic Reprogramming Driven by Metabolites

Overview

This editorial discusses the role of metabolites in metabolic reprogramming within the immune system.

Background

Metabolic reprogramming in immune cells is a critical area of research, particularly in understanding how immune responses are influenced by metabolic pathways. The recognition of metabolites as signaling molecules has opened avenues for exploring their roles in immune activation and differentiation.

Data Highlights

No numerical data or trial data presented in the editorial.

Key Findings

• Metabolites such as lactate and TMAO are recognized as signaling molecules in immune responses.
• TMAO is linked to inflammatory bowel disease (IBD).
• Macrophage metabolic profiles vary by tissue location and are influenced by dietary components and microbiota.
• Neutrophil metabolism can be influenced by interactions with platelets.

Clinical Implications

Clinicians should consider the metabolic context of immune responses when developing treatment strategies.

Conclusion

The editorial emphasizes the importance of metabolite-induced metabolic reprogramming in the immune system.

Related Resources & Content

1. Frontiers in Immunology, Editorial: Immune cell metabolism beyond energy supply – an emerging era to showcase novel roles in immune effector functions
2. Frontiers in Immunology, Editorial: Host-microbe immunometabolic chat: a new era of organismal communication
3. Frontiers in Immunology, Editorial: Community Series in Tumor Microenvironment and Metabolic Reprogramming in Cancer: Volume II
4. Frontiers in Immunology — Neutrophil immunometabolism in ACLF and sepsis: mechanisms, dysfunction, and therapeutic opportunities
5. Surviving Sepsis Campaign Adult Guidelines | SCCM
6. Overview | Suspected sepsis in people aged 16 or over: recognition, assessment and early management | Guidance | NICE
7. Dietary Management of Inflammatory Bowel Disease: an ECCO Consensus - ECCO - European Crohn’s and Colitis Organisation
8. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols | Journal for ImmunoTherapy of Cancer
9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
10. SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025) - PMC
11. Metformin enhances survival with immune checkpoint inhibitors in cancer patients: A meta-analysis - PMC
12. Metabolites as signalling molecules in the tumour immune microenvironment | Nature Reviews Immunology